← Scroll for more →
Takeda Pharmaceutical Co Ltd (TAK)
Pharmaceutical Preparations
Latest Price
$20.91
TTM P/E
--
Normalized P/E
--
TTM Div Yield
--
Fwd Div Yield
--
Book Value
--
P/B Ratio
--
Valuation metrics
adjust assumptions →EPS: $67.23
Book value / share: $4359.65
Formula: √(22.5 × EPS × BVPS)
Graham Number
$2,568.02
+12181% upside
Norm. op. income: $342.6B (median of 7yr)
Tax rate: 24%
Discount rate: 10%
Growth assumption: zero (EPV is a no-growth value)
Earnings Power Value
$1,880.11
+8891% upside
EPS: $67.23
Target P/E: 15×
Formula: EPS × P/E
P/E Fair Value
$1,008.45
+4723% upside
Institutional Ownership
6.6% held by institutions| Institution | Shares | Value | Ownership % | Change | Filing Date |
|---|---|---|---|---|---|
| Capital Research Global Investors | 19.30M | $309.0M | 1.21% | +193.5K | 2026-06-30 |
| FMR LLC | 9.60M | $153.0M | 0.60% | +2.48M | 2026-06-30 |
| Morgan Stanley | 6.99M | $112.0M | 0.44% | +525.3K | 2026-06-30 |
| Adage Capital Partners GP, L.L.C. | 6.05M | $96.0M | 0.38% | -374.2K | 2026-06-30 |
| Goldman Sachs Group Inc | 5.13M | $82.0M | 0.32% | -493.7K | 2026-06-30 |
| Brandes Investment Partners, LP | 4.54M | $72.0M | 0.29% | +108.7K | 2026-06-30 |
| Arrowstreet Capital, Limited Partnership | 3.73M | $59.0M | 0.23% | +616.6K | 2026-06-30 |
| BlackRock, Inc. | 3.69M | $59.0M | 0.23% | +511.7K | 2026-06-30 |
| Renaissance Technologies LLC | 2.57M | $41.0M | 0.16% | -421.1K | 2026-06-30 |
| Qube Research & Technologies Ltd | 2.21M | $35.0M | 0.14% | +2.01M | 2026-06-30 |